Effects of Ocrevus in Relapsing Multiple Sclerosis

The purpose of this study is to test if people with relapsing multiple sclerosis (RMS) can improve ambulatory functions after one-year treatment with Ocrevus in comparison with other Disease Modifying Treatments (DMT). Sixty qualified individuals with RMS will be evenly assigned into two groups: Ocrevus and other DMT. Each group will receive the respective treatment following the FDA regulations over the one-year course. Their ambulatory functions will be assessed five times three months apart. In addition, they will receive brain MRI scans three times six months apart. Their ambulatory functions and MRI measurements will be compared between groups over time to fulfill the purposes of this study.

NCT Number	NCT04387734
Lead Sponsor	Georgia State University Collaborators: Multiple Sclerosis Center of Atlanta
Conditions	Relapsing Multiple Sclerosis
Enrollment	60 participants
Start Date	2021-02-05
Primary Completion	2025-02-17 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-17